| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e2bbf99b6a06b466be47b7498aa8d1e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 |
| filingDate |
2009-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd61828d96e29f6b259ccc7f6f564768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f23b7403df8649edd1e2767ae54aab2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7ca893060bc8040b8063b48f4ea56c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb5212b8c965ee333c9bb1ee91660e61 |
| publicationDate |
2011-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20110103428-A |
| titleOfInvention |
Treatment of major adverse cardiac events and acute coronary syndrome with secretory phospholipase A2 (spPLA2) inhibitors or spPLA2 inhibitor combination therapy |
| abstract |
Administration of sPLA 2 inhibitors in combination with statins has been shown to reduce major adverse cardiac events (MACE), inflammatory biomarker levels and LDL-C levels in subjects who have recently experienced exponential ACS events to a significantly greater extent than statins alone. lost. These results were unexpected in light of previous results indicating that statin alone is insufficient to satisfactorily reduce MACE and inflammation in this high risk population. Therefore, methods for treating MACE, treating ACS, inhibiting inflammation, and lowering cholesterol levels in a subject who have previously experienced an ACS event by administering one or more sPLA 2 inhibitors alone or in combination with one or more statins are provided herein. Is provided. |
| priorityDate |
2008-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |